Cargando…

The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis

PURPOSE: To systematically evaluate the overall efficacy and safety of current anti-PD-1/PD-L1 antibodies for treatment of patients with advanced or refractory cancer. RESULTS: Fifty-one trials including 6,800 patients were included. The overall response rates for melanoma, non-small cell lung cance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Tengfei, Xie, Jing, Arai, Seiji, Wang, Liping, Shi, Xuezhong, Shi, Ni, Ma, Fen, Chen, Sen, Huang, Lan, Yang, Li, Ma, Wang, Zhang, Bin, Han, Weidong, Xia, Jianchuan, Chen, Hu, Zhang, Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341964/ https://www.ncbi.nlm.nih.gov/pubmed/27683031 http://dx.doi.org/10.18632/oncotarget.12230

Ejemplares similares

The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
por: Sui, Xinbing, et al.
Publicado: (2015)

A BIVALENT TIM-3/PD-1 BISPECIFIC ANTIBODY FOR THE TREATMENT OF PD-1 ANTIBODY RESISTANT OR REFRACTORY SOLID TUMORS
por: Luan, Yan, et al.
Publicado: (2023)

Combination Therapy With Anti-PD-1 or PD-1 Antibody Alone in Asian Pediatric Patients With Relapsed or Refractory Cancer
por: Que, Yi, et al.
Publicado: (2021)

Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1
por: Jiang, Mengzhen, et al.
Publicado: (2023)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
por: Yin, Zi, et al.
Publicado: (2021)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
por: Zhao, Xuan, et al.
Publicado: (2022)

Role of regulation of PD-1 and PD-L1 expression in sepsis
por: Zhang, Teng, et al.
Publicado: (2023)

Identification of a monoclonal antibody that targets PD-1 in a manner requiring PD-1 Asn58 glycosylation
por: Wang, Mingzhu, et al.
Publicado: (2019)

The significance of PD-1/PD-L1 imbalance in ulcerative colitis
por: Shi, Wei, et al.
Publicado: (2023)

Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma
por: Zhang, Xingming, et al.
Publicado: (2019)

Impact of the combined timing of PD-1/PD-L1 inhibitors and chemotherapy on the outcomes in patients with refractory lung cancer
por: Yao, W., et al.
Publicado: (2021)

Effectiveness of anti-PD-1/PD-L1 antibodies in urothelial carcinoma patients with different PD-L1 expression levels: a meta-analysis
por: Liu, Junqi, et al.
Publicado: (2018)

Patterns of treatment failure for PD-(L)1 refractory extensive-stage small cell lung cancer in continued PD-(L)1 treatment
por: Liu, Li, et al.
Publicado: (2023)

Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies
por: Tan, Shuguang, et al.
Publicado: (2016)

Association of PD-1 and PD-L1 Genetic Polymorphyisms with Type 1 Diabetes Susceptibility
por: Qian, Chenyue, et al.
Publicado: (2018)

PD-L1 Status in Refractory Lymphomas
por: Vranic, Semir, et al.
Publicado: (2016)

A phase I study of toripalimab, an anti‐PD‐1 antibody, in patients with refractory malignant solid tumors
por: Wei, Xiao‐Li, et al.
Publicado: (2020)

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
por: Wu, Mengling, et al.
Publicado: (2022)

Regulatory Effect of PD1/PD-Ligand 1 (PD-L1) on Treg Cells in Patients with Idiopathic Pulmonary Fibrosis
por: Wang, Bing, et al.
Publicado: (2021)

Targeted Glucose or Glutamine Metabolic Therapy Combined With PD-1/PD-L1 Checkpoint Blockade Immunotherapy for the Treatment of Tumors - Mechanisms and Strategies
por: Ma, Guofeng, et al.
Publicado: (2021)

Functional nanovesicles displaying anti-PD-L1 antibodies for programmed photoimmunotherapy
por: Chen, Hu, et al.
Publicado: (2022)

Treatment of patients with cancer using PD-1/PD-L1 antibodies: Adverse effects and management strategies (Review)
por: Sun, Guangshun, et al.
Publicado: (2022)

Therapeutic implications of the tumor microenvironment in ovarian cancer patients receiving PD-1/PD-L1 therapy
por: Wang, Yusha, et al.
Publicado: (2022)

Long‐term efficacy and safety of programmed death‐1 (PD‐1) antibody alone in relapsed/refractory human immunodeficiency virus‐associated Hodgkin lymphoma
por: Wang, Chaoyu, et al.
Publicado: (2022)

The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: a meta-analysis
por: Huang, Guanghong, et al.
Publicado: (2017)

The safety and efficacy of PD-1 inhibitors in patients with advanced cancers and HIV/AIDS in China
por: Xiong, Yu, et al.
Publicado: (2023)

Ocular adverse events in PD-1 and PD-L1 inhibitors
por: Young, LeAnne, et al.
Publicado: (2021)

Case report: Significant response to PD-L1 inhibitor after resistance to PD-1 inhibitor in an advanced alpha-fetoprotein-positive gastric cancer
por: Wang, Liyu, et al.
Publicado: (2022)

PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome
por: Tian, Lingyu, et al.
Publicado: (2020)

Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy
por: Issafras, Hassan, et al.
Publicado: (2021)

A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies
por: Bu, Melissa T., et al.
Publicado: (2022)

A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma
por: Guo, Weinan, et al.
Publicado: (2020)

Beyond T Cells: Understanding the Role of PD-1/PD-L1 in Tumor-Associated Macrophages
por: Lu, Di, et al.
Publicado: (2019)

Efficacy and safety of adjuvant therapy with PD‑1/PD‑L1 inhibitors in cancer
por: Mo, Dun-Chang, et al.
Publicado: (2022)

Efficacy and Safety of PD-1/PD-L1 Inhibitor Chemotherapy Combined with Lung Cancer Fang No. 1 in Relapsed and Refractory SCLC: A Retrospective Observational Study
por: Wang, Lihua, et al.
Publicado: (2022)

The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies
por: Shi, Li, et al.
Publicado: (2013)

A Partial Response of Pulmonary Pleomorphic Carcinoma to Camrelizumab (PD1 Monoclonal Antibody) Monotherapy: A Case Report
por: Chen, Yi, et al.
Publicado: (2020)

The Role of PD-L1 Expression in Prediction and Stratification of Recurrent or Refractory Extranodal Natural Killer/T-Cell Lymphoma
por: Gao, Li-Min, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_69hbihe36uvbol8qqds6nkqn9r